376 related articles for article (PubMed ID: 27981572)
1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
[TBL] [Abstract][Full Text] [Related]
2. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
Zhong X; Tong X; Ju Y; Du X; Li Y
Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
4. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
Hicks JK; Sangkuhl K; Swen JJ; Ellingrod VL; Müller DJ; Shimoda K; Bishop JR; Kharasch ED; Skaar TC; Gaedigk A; Dunnenberger HM; Klein TE; Caudle KE; Stingl JC
Clin Pharmacol Ther; 2017 Jul; 102(1):37-44. PubMed ID: 27997040
[No Abstract] [Full Text] [Related]
6. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
8. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
11. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
[TBL] [Abstract][Full Text] [Related]
12. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
[TBL] [Abstract][Full Text] [Related]
13. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.
Hashemizadeh Z; Badiee P; Malekhoseini SA; Raeisi Shahraki H; Geramizadeh B; Montaseri H
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923870
[TBL] [Abstract][Full Text] [Related]
14. Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
Williams K; Arron ST
JAMA Dermatol; 2016 Jun; 152(6):719-20. PubMed ID: 26982740
[No Abstract] [Full Text] [Related]
15. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.
Lee CR; Luzum JA; Sangkuhl K; Gammal RS; Sabatine MS; Stein CM; Kisor DF; Limdi NA; Lee YM; Scott SA; Hulot JS; Roden DM; Gaedigk A; Caudle KE; Klein TE; Johnson JA; Shuldiner AR
Clin Pharmacol Ther; 2022 Nov; 112(5):959-967. PubMed ID: 35034351
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
19. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]